Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial

  • Johan A. Maertens
  • , Issam I. Raad
  • , Kieren A. Marr
  • , Thomas F. Patterson
  • , Dimitrios P. Kontoyiannis
  • , Oliver A. Cornely
  • , Eric J. Bow
  • , Galia Rahav
  • , Dionysios Neofytos
  • , Mickael Aoun
  • , John W. Baddley
  • , Michael Giladi
  • , Werner J. Heinz
  • , Raoul Herbrecht
  • , William Hope
  • , Meinolf Karthaus
  • , Dong Gun Lee
  • , Olivier Lortholary
  • , Vicki A. Morrison
  • , Ilana Oren
    • Dominik Selleslag, Shmuel Shoham, George R. Thompson, Misun Lee, Rochelle M. Maher, Anne Hortense Schmitt-Hoffmann, Bernhardt Zeiher, Andrew J. Ullmann

Research output: Contribution to journal › Article › peer-review

840 Scopus citations

Fingerprint

Dive into the research topics of 'Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry